Merck (MRK) Q3 earnings report 2023


Merck headquarters in Rahway, New Jersey, on Tuesday, April 18, 2023.

Christopher Occhicone | Bloomberg | Getty Images

Merck on Thursday reported third-quarter revenue and adjusted earnings that topped expectations on strong sales of its blockbuster cancer drug Keytruda, HPV vaccine Gardasil and surprisingly, its Covid drug Lagevrio. 

The pharmaceutical giant also increased its full-year sales forecast to $59.7 billion to $60.2 billion, slightly higher than the $58.6 billion to $59.6 billion guidance provided in August. 

Merck lowered its adjusted profit guidance to $1.33 to $1.38 per share, from a previous forecast of $2.95 to $3.05 a share. But that updated outlook reflects an upfront…

Source cnbc.com

0 0 votes
Article Rating

UPS Q3 earnings: Revenue outlook cut

Previous article

As the market enters correction territory, don’t blame the US consumer

Next article

You may also like

Notify of
Inline Feedbacks
View all comments

More in Earnings